Objective: Evaluation of Myeloperoxidase (MPO) enzyme in Saudi patients with chronic renal failure (CRF), compared with control healthy subjects.
Back ground: The patients with renal failure are at a risk for cardiovascular diseases (CVD), MPO is a pro-oxidant enzyme, and through its strongest oxidative capacity suggested have a role in protection against CVD. In this study the level of MPO enzyme was expected to decrease in patients with CRF compared with control healthy subjects which mean that they were more vulnerable to CVD.
Methods: A case control investigated of MPO enzyme and renal function tests (urea and creatinine) levels in renal failure patients compared with a healthy subjects. Plasma MPO was assayed by a spectrophotometric method. Serum urea and creatinine were estimated on a clinical chemistry analyzer using standard laboratory procedures.
Results: The mean MPO level was significantly decreased in CRF patients compared to control healthy subjects (t=-23.737) (99% confidence intervals and t-test-23.737 significant at P < 0.01). There were significant positive correlation between MPO and Glomerular Filtration Ratio (GFR) (r=0.657, P < 0.01) and significant inverse correlation with Urea (r=-.729, P < 0.01) and Creatinine (r=-0.772, P < 0.01). No correlations observed in control healthy subjects (P = 0.97).
Conclusion: The level of MPO was significantly decreased in patients with CRF, this decreased may be due to inhibition of uremic toxins.
Oxidative stress, Uraemic toxins, Cardiovascular disease (CVD).